Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Life Technologies Signs Stem Cell Agreement with Harvard University

Published: Tuesday, March 05, 2013
Last Updated: Tuesday, March 05, 2013
Bookmark and Share
Research collaboration aimed at yielding standardized method for evaluating iPS cell quality; deepens Life's investment to its expanding stem cell product portfolio.

Life Technologies Corporation announced that it has signed a collaborative research agreement and related license with Harvard University under which it has acquired exclusive rights to develop a panel of characterization assays designed to rapidly evaluate human pluripotent stem (hPS) cells for their utility in a variety of discovery and translational research applications. The license expands Life's growing portfolio of stem cell research products and deepens its commitment to customers in the field.

The panel, which will be offered on the company's market-leading semiconductor sequencing and PCR-based genetic analysis platforms, will help overcome major hurdles that impede stem cell technology from moving into the clinic. Current methods for evaluating pluripotency — the potential for induced pluripotent stem (iPS) cells to differentiate into any cell type — are laborious, costly and can produce ambiguous results.

Standardizing the way researchers characterize iPS cells will allow them to quickly identify the most promising cell lines and avoid wasting time and resources on cells that do not possesses the appropriate characteristics. Such efficiency could accelerate applications ranging from development of "disease-in-a-dish" models from patient-derived cells and drug screening, to the eventual use of pluripotent cells as a renewable source for transplantation medicine.

"As iPS cell research grows in scale and moves closer to the clinic, investigators are increasingly in need of characterization standards that enable them to make informed decisions about the quality of their cells," said Chris Armstrong, Ph.D., General Manager and Vice President of Primary and Stem Cell Systems at Life Technologies. "Our investment in this important work developed at Harvard University supports our sustained commitment to provide our customers with the most innovative tools for the iPS cell workflow."

The panel of assays was developed by Alex Meissner, Ph.D., Associate Professor, Department of Stem Cell and Regenerative Biology, Harvard University, and is being further studied and validated in collaboration with Life Technologies. Dr. Meissner is the lead author of a study in the journal Cell (Vol. 144, No. 3, pp. 439-452, Feb. 4, 2011) that identified a range of expression levels among key genes associated with pluripotency. By measuring gene activity in iPS cells against the study's gene expression range, Meissner's lab was able to accurately score cells for their potential to differentiate into particular cell lineages.

"Stem cell research and genomics have rapidly advanced in parallel over the past few years," said Dr. Meissner. "Combining both fields of study is enabling more effective and standardized ways of characterizing pluripotent cells and, therefore, greatly improving efficiency and the application of iPS cells."

Considered a growing segment in the field, the global stem cell characterization market is currently estimated to be $30 million per year, while the overall market for the stem cell research tools is approximately $1 billion, according to BioInformatics LLC.

This announcement marks the third major license agreement in less than a year for Life Technologies' Primary and Stem Cell Systems group. In June 2012, the company retained the non-exclusive global rights from iPS Academia Japan for its iPS cell patent portfolio — enabling Life Technologies to expand its range of products and services. That same month, the company also announced a partnership with Cellular Dynamics International (CDI), the world's largest producer of human cells derived from (iPS) cells, to commercialize a set of new products optimized to consistently develop and grow human iPS cells.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Life Technologies Extends Partnership with DNAVEC
R&D collaborative agreement aims to further develop Sendai virus-based tools for basic and translational research.
Monday, October 21, 2013
Life Technologies Announces Second Quarter 2013 Results
Revenue increased 1% excluding impact of currency.
Thursday, August 01, 2013
Life Technologies Acquires KDR Biotech
The acquisition is part of Life Technologies strategic international growth plan in fast-growing markets.
Friday, April 12, 2013
Life Technologies Names Alan Sachs as Head of Global Research and Development
Sachs brings more than 20 years of experience as a research scientist and a leader in developing innovative scientific platforms.
Wednesday, February 01, 2012
Scientific News
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Challenging Stem Cell Fate Control
Researchers have found that the fate of stem cells is not only controlled by their local niche, but also by a cell-intrinsic mechanism.
Zika Proteins Responsible for Microcephaly Identified
Researchers have undertaken the first study to examine Zika infection in human neural stem cells from second-trimester fetuses.
Heart Muscle from Stem Cells Aid Cardiovascular Medicine
Researchers discover heart muscle cells from stem cells mirror expression patterns of key genes in donor tissue.
Examining New Hypotheses for Undiagnosed Patients
UnDx Consortium gathers in San Diego to create new paths to identifying currently undiagnosed illnesses.
Novel Therapeutic Approach for Blood Disorders
Gene editing of human blood-forming stem cells mimics a benign genetic condition that helps to overcome sickle cell disease and other blood disorders.
Bone Marrow Transplants Without Using Chemotherapy
Scientists have devised a way to destroy blood stem cells in mice without using chemotherapy or radiotherapy, both of which have toxic side effects.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Two Zika Proteins Responsible For Microcephaly Identified
It’s the first study to examine Zika infection in human neural stem cells from second-trimester fetuses, USC researchers say.
Directly Reprogramming a Cell's Identity with Gene Editing
Duke engineers use CRISPR to generate neuronal cells from connective tissue.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!